Zeta ER Antibody. Zeta’s recombinant mouse antibody recognizes ER (Estrogen Rceptor), which belongs to the steroid receptor superfamily of nuclear receptors. ER (Estrogen Receptor) is a protein of 553 amino acids with three domains (the central DNA-binding domain, the hormone-binding domain at the C-terminal, and the transcription-activating domain at the N-terminal). ER (Estrogen Receptor) mediates regulatory functions of female sex steroids for growth, differentiation, and function in several target tissues, including the female and male reproductive tract, mammary gland, and skeletal and cardiovascular systems. Studies have shown ER is present in the nuclei of epithelial cells in normal breast and endometrial tissues and a subset of breast carcinomas. Studies with immunohistochemical assay show that ER positive steroid hormone status has predicted favorable overall survival, independently of hormonal treatment. ER acts as a tumor marker, preferentially in combination with an antibody to the Progesterone Receptor (PR) in the classification of adenocarcinomas.
ER expression in breast cancer and can serve as a good prognostic factor in invasive breast carcinomas and endometrial carcinomas and as an indicator of response to hormonal treatment. The ER antibody shows nuclear positivity. ER testing is recommended for invasive breast cancer as the standard for predicting which patients may benefit from endocrine therapy and for testing of ductal carcinoma in situ (DCIS).
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.